The Company entered into a Distribution
and License Agreement with a third-party for the purpose of developing a sensor array to be used in the Company’s product.
The Distribution and License Agreement has an initial term of ten years, but can be terminated earlier if the project does not
meet the specifications of the Company. The Company will obtain exclusive rights to sell and distribute once a successful sensor
prototype is developed. In exchange for a functional prototype, the Company will pay the third-party a 7% royalty on net sales.
During the nine months ended September 30, 2018, the Company did not incur any development costs related to the Distribution and
License Agreement.

On November 1, 2013, the Company entered
into a two-year Joint Development Agreement (the “Agreement”) with an unrelated third-party to develop chemical sensors
and peripheral sensing equipment and software for the detection and characterization of cannabis and compounds associated with
cannabis.

The Agreement provides for, among other
things, any arising intellectual property rights (as defined) outside of the field (as defined), and any arising intellectual property
rights relating to improvements to detection materials shall belong to the Joint Venture Developer.

The Agreement also provides that any arising
intellectual property rights other than those covered above shall belong to the Company. To the extent that it is necessary to
do so to enable the Company to use and exploit its respective arising intellectual property rights, the Joint Developer grants
the Company a perpetual, irrevocable, exclusive, and royalty free license (including the right to assign the license and to grant
sub-licenses) to use and exploit the Joint Developer’s arising intellectual property rights in the field. Under the terms
of the Agreement, either party may cancel the Agreement as the specific tasks provided for in the Agreement have been completed
or for causes specifically provided for in the Agreement.

On May 19, 2015, the Company entered into
an Exclusive Patent Sublicense Agreement (the “License Agreement”) with Next Dimension Technologies, Inc. (“NDT”).
The License Agreement grants the Company a worldwide right to the patents licensed by NDT from the California Institute of Technology.
The License Agreement grants both exclusive and non-exclusive patent rights. The license granted in the License Agreement permits
the Company to make, have made, use, sell and offer for sale sublicensed products in the field of use. The License Agreement continues
until the expiration, revocation, invalidation or enforceability of the rights licensed. The License Agreement provides for the
payment of a license fee and royalty payments by CDx to NDT. The License Agreement also contains minimum royalty payments and milestone
payments by CDx to NDT. NDT has a right to terminate the License Agreement in the event of an uncured breach by CDx; the insolvency
or bankruptcy of CDx; or if CDx does not meet certain productivity milestones. The License Agreement also contains representations,
warranties and indemnity obligations for each of CDx and NDT. In connection with the License Agreement, on May 19, 2015, CDx and
NDT also executed an Amended Amendment No. 4 (the “Amended Amendment No. 4”) to the Joint Development Agreement, dated
as of November 1, 2013, between CDx and NDT, which extended the date of negotiation for the License Agreement through May 19, 2015.

On February 8, 2017, MyDx, Inc. entered
into an option agreement (the “Option Agreement’) with the Torque Research & Development, Inc. (“TRD”).
The Option Agreement provides MyDx with the exclusive right to license two patent pending inventions (the “TRD Inventions”),
and requires MyDx to make annual payments to TRD as well as royalty payments on any products that are commercialized which are
based on the TRD Inventions. MyDx’s rights under the Option Agreement require customary measures of performance on the part
of MyDx in terms of patent cost maintenance and other payments of costs associated with the TRD Inventions. With respect to the
Option Agreement, MyDx rights are broad in terms of the potential access MyDx has to use the TRD Inventions in products, and services
and many of the key economic terms of a future license, should MyDx exercise its rights under the Option Agreement, are agreed
to in the Option Agreement.

In addition to the Option Agreement with
the TRD, on February 8, 2017, MyDx has entered into a research and development agreement (the “RD Agreement”) with
TRD for the Project titled “Manufacturable, Medical Grade Smart Vape Devices and Related Medical Software Applications for
Prescribers, Administrators and Patient Applications.” The RD Agreement allows MyDx to fund research based on the TRD Inventions
with a three year budget of $280,371 and a deferred payment of $75,000 within ninety days of the Effective Date. The RD Agreement
provides MyDx with an exclusive right to license all technology that is discovered from the monies funded to TRD through the RD
Agreement (the “Derivative IP”). To the extent that MyDx exercises its rights under the RD Agreement, MyDx will be
required to make customary annual payments to TRD, who shall be the owners of any Derivative IP, as well as royalty payments as
any commercialization of such Derivative IP occurs. TRD may elect to accept payment in whole or in part in cash or the companies
restricted common stock priced at the Effective Date. During the nine months ended September 30, 2018, the Company converted the
vendor liability into 45,355 Series B Preferred shares. In connection with this transaction the Company recorded a loss on settlement
of vendor liability of $5,233,314.

On January 26, 2018 the Company entered
into a joint venture with Ganja Gold to form “NewCo”. With the formation of NewCo, the intent is for the Parties to
manufacture and distribute a new premium line of physiological based Vape formulations under Ganja Gold Vape Brand (“GGV
Brand”). The GGV Brand will be powered by MYDX data and formulations utilizing the Eco Smart Pen Device under an exclusive
license of MYDX Power Formulations. MyDx will have the option to acquire 50% of NewCo.

License and Distribution Agreement

On June 12, 2017, MyDx, Inc. (the “Company”
or “Licensor”) entered into a license and services agreement (the “License Agreement”) with Black Swan,
LLC (the “Licensee”). The Licensor agrees to grant to the Licensee the Access License which shall consist of:

(a)

access to the database to enable Licensee to engage in formulation queries regarding the effects of having different amounts of terpene or other chemicals in cannabis strains;

(b)

access to the database’s chemical profile library and related definitions;

(c)

access to a list with the contact information and fee schedule of cannabis extractors with state licenses so that Licensee can submit the formulation query results to such licensed cannabis extractors. Such licensed extractor list may change and Licensor shall have no obligation to provide Licensee with an updated list; and

(d)

access to the CannaDxTM mobile application to track feedback and reviews by up to 20,000 users of Licensee’s products.

The Licensor will provide the Product Services
which shall consist of:

Licensor providing 6,000 Cartridges every six months to the Licensee at a cost of $2.49 per Cartridge ($14,940 in total every six months). It shall be a requirement of this Agreement that Licensee order 6,000 Cartridges from Licensor every six months;

(3)

Licensor providing 1,000 Eco Smart Pens to the Licensee, when available, over the three-year term of this Agreement at a cost of $25 per Eco Smart Pen ($25,000 in total); and

(4)

Licensor providing 6,000 batteries to the Licensee over the three-year term of this Agreement at a cost of $3.99 per battery ($23,940 in total).

The term of this Agreement shall be three
(3) years. Licensor shall have the right, in its sole discretion, to terminate this Agreement if Licensee does not order and pay
for at least 6,000 Cartridges every six months at a cost of $2.49 per Cartridge ($14,940 in total every six months).

On April 26, 2018, MyDx, Inc. (the “Company”
or “Licensor”) entered into a license and services agreement (the “License Agreement”) with Humanity Holdings
(the “Licensee”). The Licensor agrees to grant to the Licensee access to the MyDx360 platform. The Licensor agrees
to issue the Licensee $25,000 of shares on the 45th day anniversary of this agreement. These shares will vest with achievement-based
milestones. As of the date of this filing these shares have not been issued. The Licensee will pay a support and service fee equal
to 20% of net sales and a royalty of 30% of net sales. The term of this Agreement shall be two (2) years.

Marketing and Advertising Advisory
Services Agreement

On April 5, 2016, the Company entered into
a Marketing and Advertising Advisory Services Agreement (the “Agreement”) with Growth Point Advisors, Ltd. (“Growth
Point”) for Growth Point to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region
on behalf of the Company’s MyDx AquaDx sensor. The campaign shall include, but not be limited to, the development of both
the front and back-end of an e-commerce web site targeting the Chinese audience as well as introductions to potential key personnel
to launch and manage the campaign.

In consideration for the services described
above, the Company shall pay Growth Point a monthly service fee of $30,000. Should the Company fail to pay the monthly service
fee, Growth Point shall have the right to convert the monthly service fee into the Company’s common stock at a 50% discount
of the lowest closing price of the Company’s common stock for the 15 trading days upon send notice of non-payment to the
Company.

On May 16, 2017, the Company terminated
its Marketing and Advertising Advisory Services Agreement with Growth Point Advisors, Ltd. (“Growth Point”) entered
into in April 2016. Growth Point had been expected to provide a comprehensive marketing, advertising and branding campaign for
the Greater China Region on behalf of the Company’s MyDx AquaDx sensor. Growth Point failed to satisfy the agreed upon deliverables
as stated in the agreement. As of the date of this filing the Company has not received communication from Growth Point.

On February 17, 2017 MyDx and Libre Design,
LLC (“LDL”) entered into a twelve (12) month Research, Branding, Advertising and Marketing Services Agreement (“Agency
Agreement”). The Company agreed to pay deferred cash compensation as follows of three thousand dollars ($3,000) upon execution
and one thousand five hundred dollars ($1,500) per month for a subsequent eleven (11) payments thereafter on or before the first
(1st) of each month. In addition, Agency is entitled to receive sixty seven million shares of restricted common stock at a closing
market price equal to $0.0011.

On March 1st and 15th, 2017, MyDx, Inc.
received a payment demand for the initial and subsequent payment of $50,000 and $25,000 per month respectively, exclusive of costs
and other fees, due and owing under the BCI Advisors, LLC (“BCI”) advisory services agreement (the “Advisory
Services Agreement”). The Company elected in lieu of cash to pay in unrestricted common stock, registered in form S-8. The
Company made an initial payment of seventy five million shares in partial satisfaction of the amount due and owing that does not
exceed the Company’s obligations under the Advisory Services Agreement to restrict BCI’s beneficial ownership to 4.99%.
During the nine months ended September 30, 2018 this agreement was canceled and the Company converted the vendor liability into
38,272 Series B Preferred shares. In connection with this transaction the Company recorded a loss on settlement of vendor liability
of $2,884,074.

On November 3, 2017 the Company and Phylos
Bioscience, Inc. (“Phylos”) entered into a License, Co-Marketing, and Data Sharing Agreement (the “Phylos Agreement”).
Pursuant to the Phylos Agreement, the Company and Phylos each granted a non-exclusive license to the other party to access their
data and use their trademarks and logo on marketing materials. Neither party paid cash or issued shares in connection with the
Phylos Agreement. The license was the consideration given by each party. The term of the Phylos Agreement is five (5) years.

On February 1, 2018 MyDx and Erai Beckmann
entered into a twelve (12) month Research, Manufacturing, Advertising and Marketing Services Agreement. The Company agrees to pay
$15,000 in restricted common stock on the first day of each quarter. In addition, Erai Beckmann is entitled to 2,500,000 of the
Company’s common stock on the 60th day anniversary of this agreement.

Litigation

In the normal course of business, the Company
may be subject to other legal proceedings, lawsuits and other claims. Although the ultimate aggregate amount of probable monetary
liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with
assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other
matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations
or cash flows.

However, there can be no assurance with
respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially
from those projected.